Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD117/amanitin antibody-drug conjugate MGTA-117

An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), conjugated, via a cleavable linker, to the cytotoxic RNA polymerase II inhibitor amanitin, with potential antineoplastic activity and that can potentially be used as a conditioning agent to selectively deplete hematopoietic stem cells (HSCs) prior to allogeneic HSC transplants or other treatments for which HSCs need to be depleted. Upon administration of the anti-CD117/amanitin ADC MGTA-117, the antibody moiety targets and binds to the cell surface antigen CD117. Upon internalization and cleavage, the cytotoxic amanitin is released, binds to and inhibits RNA polymerase II. This prevents RNA synthesis and induces apoptosis of CD117-overexpressing HSCs and leukemic blasts. CD117, a transmembrane protein and receptor tyrosine kinase, is highly expressed on HSCs, progenitor cells and on leukemia cells. MGTA-117 is engineered to have a short half-life.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC MGTA-117
anti-c-Kit/amanitin ADC MGTA-117
anti-CD117 ADC MGTA-117
Code name:MGTA 117
MGTA-117
MGTA117
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search